

Novartis at ASH ^[1]

Publish Date: 02 December 2020 16:00 CET



Novartis 2020 ASH Annual Meeting Virtual Portal

Novartis presence at ASH:

[Enter Portal](#) ^[2]

Press releases

- [Data from more than 65 abstracts showcase Novartis focus on delivering transformative innovation for blood cancers and serious hematologic diseases at ASH20](#) ^[3]
 - [New Novartis data from pivotal Phase III REACH3 study in chronic graft-versus-host disease presented at ASH20](#) ^[4]
 - [Novartis to present new analyses from ELARA and JULIET trials of CAR-T cell therapy for patients with certain advanced lymphomas at ASH20](#) ^[5]
 - [Exciting new late-breaker data from Novartis on novel, investigational STAMP inhibitor in chronic myeloid leukemia at ASH20](#) ^[6]
-

Our commitment to blood cancers and blood disorders:

[Video of Reimagining cancer and blood disorders](#)

Source URL: <https://www.novartis.com/news/novartis-ash>

Links

[1] <https://www.novartis.com/news/novartis-ash>

[2]

https://www.virtualcongress.novartis.com/ash20/?utm_medium=referral&utm_source=novartis.com&utm_c

[3] <https://www.novartis.com/news/media-releases/new-data-ash-reinforce-breadth-novartis-hematology-portfolio-across-multiple-blood-cancers-and-serious-hematologic-diseases>

[4] <https://www.novartis.com/news/media-releases/novartis-announces-first-data-from-reach3-trial-showing-jakavi-ruxolitinib-significantly-improved-outcomes-patients-steroid-resistantdependent-chronic-gvhd>

[5] <https://www.novartis.com/news/media-releases/novartis-analyses-confirm-benefit-kymriah-clinically-meaningful-rates-complete-response-seen-patients-certain-advanced-lymphomas>

[6] <https://www.novartis.com/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial>